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Abstract
Introduction The aim of this study is to evaluate whether the
diagnostic accuracy of 3 T brainMRI is improved by region of
interest (ROI) measures of diffusion tensor imaging (DTI), to
differentiate between neurodegenerative atypical parkinson-
ism (AP) and Parkinson’s disease (PD) in early stage
parkinsonism.
Methods We performed a prospective observational cohort
study of 60 patients presenting with early stage parkinsonism
and initial uncertain diagnosis. At baseline, patients
underwent a 3 T brain MRI including DTI. After clinical
follow-up (mean 28.3 months), diagnoses could be made in
49 patients (30 PD and 19 AP). Conventional brain MRI was
evaluated for regions of atrophy and signal intensity changes.
Tract-based spatial statistics and ROI analyses of DTI were
performed to analyze group differences in mean diffusivity
(MD) and fractional anisotropy (FA), and diagnostic thresh-
olds were determined. Diagnostic accuracy of conventional
brain MRI and DTI was assessed with the receiver operating
characteristic (ROC).
Results Significantly higher MD of the centrum semiovale,
body corpus callosum, putamen, external capsule, midbrain,
superior cerebellum, and superior cerebellar peduncles was
found in AP. Significantly increased MD of the putamen
was found in multiple system atrophy–parkinsonian form
(MSA-P) and increased MD in the midbrain and superior cer-
ebellar peduncles in progressive supranuclear palsy (PSP).
The diagnostic accuracy of brain MRI to identify AP as a
group was not improved by ROI measures of MD, though
the diagnostic accuracy to identify MSA-P was slightly in-
creased (AUC 0.82 to 0.85).
Conclusion The diagnostic accuracy of brain MRI to identify
AP as a group was not improved by the current analysis ap-
proach to DTI, though DTI measures could be of added value
to identify AP subgroups.
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Introduction
Brain MRI is commonly performed in the diagnostic workup
of parkinsonism. The main purpose of this study is to assess
cerebrovascular damage for the diagnosis of vascular parkin-
sonism and to exclude other possible but more rare causes of
parkinsonism (e.g., multiple sclerosis). It can also show ab-
normalities which are suggestive of neurodegenerative atypi-
cal parkinsonism (AP) [1–3]. Examples include atrophy and
T2 hypo-intensity of the putamen, which can be seen in the
parkinsonian form of multiple system atrophy (MSA-P),
while signal intensity changes of the pons (Bhot cross bun^
sign) or pontocerebellar atrophy can point to the cerebellar
form of MSA (MSA-C). Atrophy of the midbrain
(Bhummingbird^ sign) or signal intensity changes in the supe-
rior cerebellar peduncles are suggestive of progressive
supranuclear palsy (PSP). Asymmetrical cortical atrophy is
the hallmark of Corticobasal degeneration (CBD). Conven-
tional brain MRI is usually normal or will show age-related
changes in early stage Parkinson’s disease (PD), which is the
most frequent cause of parkinsonism [4]. Later on, cortical
atrophy of the frontal or temporal lobe can be seen in PD.
Although certainty about the diagnosis increases during
clinical follow-up, the aim of ancillary investigations is to
increase certainty about the diagnosis in early disease stages,
which is important for adequate patient counseling and to
some extent also treatment [5]. It has been shown that the
added value of conventional brain MRI in the diagnostic
workup of parkinsonism is highest in case there is uncertainty
about the diagnosis [6].
In recent years, new MRI techniques have become avail-
able for clinical practice, including diffusion-weighted imag-
ing (DWI) and diffusion tensor imaging (DTI). DiffusionMRI
quantifies the random movement of water molecules and
seems to represent a quantitative measure of microstructural
changes in neurodegenerative pathology, even when no ab-
normalities are seen on conventional MRI sequences. While
fractional anisotropy (FA) estimates the degree of anisotropy,
i.e., restriction of the random motion of water molecules by
the normal architecture of glial tissue and fiber tracts, mean
diffusivity (MD) is an averagedmeasure of diffusivity. Loss of
microstructural integrity of brain tissue is commonly reflected
by a decrease in FA and an increase in MD. Two main quan-
titative analyses for diffusion MRI include the region of inter-
est (ROI) method and the automated voxel-based methods.
Tract-based spatial statistics (TBSS) is an example of the au-
tomated voxel-based method. These two approaches yield
complementary results, but each method has its drawbacks
and does not completely reflect ongoing changes [7].
Different patterns of microstructural changes can be iden-
tified by DTI in PD and the different forms of AP, which seem
to correlate with known histopathologic changes in these dis-
eases [8–10]. Examples include increase in MD and decrease
in FA of the putamen or pontocerebellar structures in MSA,
and diffusional changes of the midbrain and superior cerebel-
lar peduncles in PSP [10]. Previous studies indicate that DTI
measures of the basal ganglia, brainstem, and cerebellum can
accurately identify subjects diagnosed with PD and different
forms of AP [8, 11]. Despite of the positive study results,
actual application of quantitative DTI in clinical practice is
limited because validated diagnostic criteria are generally
lacking and no clear guidelines are available how to interpret
quantitative diffusional data of the individual patient. Also,
few studies evaluated brain MRI and DTI in early disease
stages where the added value of brain MRI is most clinically
relevant [12, 13].
Our study objective was to evaluate whether ROI measures
of DTI improve the diagnostic accuracy of conventional 3 T
brain MRI in the diagnostic workup of early stage parkinson-
ism, to differentiate between Parkinson’s disease and neuro-
degenerative atypical parkinsonism.
Material and methods
Study group
We performed a prospective observational cohort study of 60
patients presenting with parkinsonism. Patients were consec-
utively recruited at our outpatient movement disorder clinic in
the period 2010–2012. Study inclusion criteria were clinical
signs and symptoms of parkinsonism (hypokinetic-rigid syn-
drome of neurodegenerative origin), with an uncertain clinical
diagnosis and disease duration less than 3 years. Exclusion
criteria were age below 18, prior brain surgery, presence of
other neurological diseases, and instable comorbidity. The
medical ethics committee of our hospital approved the study
and all participants gave written informed consent.
Study design
Clinical examination of all patients was performed at baseline
by an experienced physician (MA, AR) and included stan-
dardized history taking and neurological examination.
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Cardiovascular risk factors, activities in daily living, medica-
tion use (including response to anti-parkinsonian medication),
disease onset, clinical signs, most affected body site, balance,
and fear of falling were assessed. Clinical neurological scores
were applied, including the Non-Motor Symptom Scale
(NMSS) [14], Unified Parkinson’s Disease Rating Scale
(UPDRS-III) for evaluating severity of motor symptoms
[15], the Mini-Mental State Examination (MMSE) to evaluate
global cognitive status [16], and Hoehn and Yahr staging scale
(H&Y) for assessing disease severity [17].
At baseline, all patients had a brain MRI. After clinical
follow-up, final diagnoses could be made by two experienced
clinicians (AR, RE) according to international diagnostic
criteria [18–24] based on neurological signs that developed
during the course of the disease (as identified during repeat
neurological exams), rate of disease progression, and treat-
ment response. Using these Bsilver standard^ diagnoses, the
ability of brain MRI and DTI to differentiate between PD and
AP was evaluated.
Brain MRI scanning protocol
All patients had a 3 T brain MRI study (Magnetom Trio,
Siemens, Erlangen, Germany). Total acquisition time was
42 min and included a 7-min, 24-s DTI acquisition. A 12-
channel receive-only phased-array head coil was used. Con-
ventional brain MRI included the following: 3D T1 MP
RAGE (TR/TE=2300/4.71 ms, flip angle=12°, voxel size
1×1×1 mm, FOV=256 mm), T2 TSE (TR/TE=5830/
120 ms, flip angle=120°, voxel size 0.6×0.6×3 mm, FOV=
240 mm), T2 FLAIR (TR/TE=9000/86 ms, flip angle=150°,
voxel size 0.7×0.6×5 mm, FOV=240 mm), proton density
(TR/TE=2000/20 ms, flip angle=90°, voxel size 0.9×0.9×
3 mm, FOV=240 mm), and DWI (TR/TE=3900/89 ms, b
values 0 and 1000 s/mm2, flip angle=90°, voxel size 1.3×
1.3×5 mm, FOV=240 mm) sequences.
Details of the DTI sequence were as follows: single-shot
spin-echo EPI, b values 0 and 1000 s/mm2, TR/TE=13,000/
102 ms, number of encoding directions=30, FOV=240 mm,
and voxel size 2×2×2 mm.
Imaging analysis
Two neuroradiologist (FJAM, 5 years of experience, and BG,
30 years of experience) evaluated conventional brain MRI
studies in a standardized manner, blinded to clinical informa-
tion. The following abnormalities were scored for the evalua-
tion of parkinsonism [2, 3, 6, 25]: atrophy and T2 hypo-
intensity of the putamen, putaminal rim sign, pontine atrophy,
hot cross bun sign, cerebellar atrophy, T2 hyper-intensity, and
atrophy of the middle cerebellar peduncle (MCP) were scored
as indicators of MSA. Midbrain atrophy, hummingbird sign,
and reduced AP midbrain diameter <14 mm were scored as
indicators of PSP. Cortical atrophy and third and lateral ven-
tricle dilatation were scored as indicators for either CBD or
LBD. Furthermore, white matter T2 hyper-intensity changes
and the presence of infarction were scored.
The in-house developed algorithm named BPATCH^ [26]
was employed to the raw DTI data to detect and correct head
and cardiac motion artifacts and eddy currents using an itera-
tively reweighted least squares algorithm. Corrections of eddy
current and motion artifacts were performed simultaneously.
First, a TBSS analysis was performed. FA and MD were
calculated using DTIFit within the FSL toolbox (Functional
MR Imaging of the Brain Software Library, University of
Oxford, United UK; http://www.fmrib.ox.ac.uk/fsl/), which
were fed into the TBSS pipeline. This pipeline includes the
thinning procedure using the mean FA image to create a
common skeleton, which represents the core structure of the
white matter tract. The FA threshold value of 0.2 was applied
to include major white matter tracts. These projection vectors
were then applied to MD.
Next, a ROI analysis was performed. DTI data were nor-
malized to the MNI space using nonlinear registration with
Statistical Parametric Mapping (SPM, Trust Centre of Neuro-
imaging, London, UK; http://www.fil.ion.ucl.ac.uk/spm/). All
images and maps were visually inspected for error or
mismatch. Using the FMRIB58_FA standard-space FA tem-
plate, 16-mm2 ROIs were placed in the following gray and
white matter structures, which are known to be affected in the
different disease entities: bilateral midbrain at the level of the
substantia nigra (MNI coordinates 6 and −6, −14, −4), thala-
mus (10 and −10, −20, 0), putamen (28 and −28, −1,0), cau-
date nucleus (12 and −12, 18, 0), globus pallidus (16 and −16,
2, −2), superior cerebellar peduncle (SCP) (6 and −6, −36, −
20), MCP (20 and −20, −42, −34), dentate nucleus (14 and −
14, −56, −30), and the pons (0, −28, −32) (Fig. 1). Matlab
(MathWorks, Natick, MA) was used to calculate MD and FA
values of these ROIs. ROI placement was visually checked in
correlation with conventional brain MRI for each dataset and
corrected if necessary.
Statistical analyses
TBSS analysis A two-sample t test using permutation-based
statistical interference as a part of FSL toolbox (Brandomise^)
was performed with 5000 permutation sets, corrected for mul-
tiple comparisons across space using the threshold-free cluster
enhancement to compare MD and FA of PD with AP and PD
with AP subgroups.
ROI analysis Mean MD and FA values of the different
ROIs were calculated for each disease group, and one-
way ANOVA, corrected for multiple comparisons with a
Bonferroni correction, was performed to analyze group
differences. A p value below 0.05 was considered
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statistically significant. Threshold values of MD or FA
were chosen based on optimal sensitivity and specificity
to discriminate AP from PD using receiver operating char-
acteristic (ROC) analyses. The summation of DTI mea-
sures above defined thresholds was used to evaluate the
diagnostic performance of DTI.
Inter-rater variability of the abnormalities scored on con-
ventional brain MRI was analyzed with the use of Cohen’s
kappa coefficient, defined as follows: <0.20, poor agreement;
0.21–0.4, fair agreement; 0.41–0.60, moderate agreement;
0.61–0.80, good agreement; and >0.80, perfect agreement.
Diagnostic performance of brain MRI was assessed based on
the summation of all abnormal findings. The ROCwas used to
evaluate the discriminative power of brain MRI alone and
combined with selected DTI ROI measures. Statistical analy-
ses were performed with SPSS (IBM SPSS statistics 20).
Results
Study group
After clinical follow-up (mean 28.3±8.8 months), probable
diagnoses of PD or AP could be made in 49 of the 60 patients:
30 patients were diagnosed with PD and 19 patients with AP.
Eleven patients had to be excluded from the analyses for the
following reasons: brain MRI with severe artifacts (n=2), un-
certain diagnosis (n=6), diagnosis other than PD or AP (n=2),
and diagnosis of vascular parkinsonism (n=1). Vascular par-
kinsonism was excluded because our primary interest was
neurodegenerative atypical parkinsonism.
Mean duration of follow-up was longer for PD patients
(31.2±6 months) than for AP (23.7±10 months). The group
of AP included 12 patients diagnosed MSA-P, 3 patients PSP,
3 patients DLB, and 1 patient CBD. In comparison to PD, the
group of AP had a statistically significant longer disease du-
ration (mean 28.4 vs 21.6 months), higher scores of disease
severity (H&Y mean score of 2.4 vs 1.7), and severity of
motor symptoms (UPDRS-III mean score of 43.5 vs 31.6).
Demographic data are summarized in Table 1.
DTI analyses
Tract-based spatial statistics
Results of TBSS analyses to compare AP (n=19) with PD (n=
29) and to compare MSA-P and DLB with PD are shown in
Fig. 2. One patient diagnosed with PD had to be excluded
because normalization of DTI to the MNI space failed.
A symmetric pattern of bilateral higher MD of the follow-
ing white matter structures was found for AP in comparison to
PD patients (statistically significant, p<0.05): centrum
semiovale, body corpus callosum, external capsule, and supe-
rior part of the cerebellum. In addition, the subcortical white
matter of the left superior frontal gyrus showed significantly
higherMD for AP in comparison to PD subjects. Significantly
lower FA of the centrum semiovale was found for AP, pre-
dominantly on the left side. The other brain structures did not
show significant differences in FA between PD and AP.
In a TBSS comparison betweenMSA-P and PD,MDof the
putamen and external capsule on the left side, and the superior
part of the cerebellar vermis proved to be statistically signifi-
cant higher in MSA-P (p<0.05). A part of the left external
capsule demonstrated significantly lower FA in MSA-P in
comparison to PD. Near statistically significant higher MD
of the right putamen and external capsule was observed in
MSA-P (p<0.1).
Higher MD and lower FA of the anterior part of the cen-
trum semiovale and genu corpus callosum on the left side was
found for DLB in comparison to PD, though this difference
was not statically significant (p<0.1). TBSS to compare PSP
with PD did not show differences in MD or FA, especially no
differences in diffusivity were demonstrated in the superior
cerebellar peduncles for PSP.
Fig. 1 Regions of interest in the
bilateral putamen (a), midbrain
(b), and superior cerebellar
peduncles (c). Mean MD and FA
of these ROIs were calculated
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Region of interest analyses
The brain structures which demonstrated significantly higher
MD in different forms of AP are summarized in Table 2; mean
MD and FA measures of the all brain structures evaluated in
our study are provided in the Appendix. MD values of the
putamen were significantly higher for MSA-P in comparison
to PD, but also higher than the other forms of AP (though not
reaching statistical significance). MD values of the left SCP
were significantly higher in MSA-P in comparison to PD but
comparable to PSP and DLB. In PSP, significantly higher MD
values of the midbrain and right SCP were observed in com-
parison to the other diseases. No diffusional changes were
observed for PD or DLB in comparison to the other diseases.
Figure 3 shows boxplots of the distribution of MD values
for the different diseases. Based on additional ROC analyses
to determine optimal sensitivity and specificity, threshold MD
values were determined to discriminate AP from PD: MD
value of 0.9×10−3 mm2/s for the putamen and midbrain, and
1.1×10−3 mm2/s for the SCP. Subjects with MD values above
one of these thresholds consisted mainly of patients diagnosed
with AP. The MD cutoff thresholds for these structures were
applied to our cohort and the summation of results was used
for the evaluation of the diagnostic accuracy of DTI to identify
AP.
Diagnostic accuracy of brain MRI and DTI
Abnormalities scored on conventional brain MRI are summa-
rized in Table 3. As described earlier, the putaminal rim sign
noted on 3 T brain MRI is a normal finding and not indicative
of AP [27]. In our study, we confirm that this finding has no
diagnostic value in the identification of MSA-P (sensitivity 33
%, specificity 51%) or AP (sensitivity 37% and specificity 50
%). This was the reason that we did not include the putaminal
rim sign in our analysis to evaluate the performance of con-
ventional brain MRI.
Atrophy and T2 hypo-intensity of the putamen, the hum-
mingbird sign, and lateral ventricle dilatation proved to have
perfect inter-rater agreement (kappa >0.92). Inter-rater agree-
ment was good for T2 hyper-intensity changes of the middle
cerebellar peduncle, cortical atrophy, and third ventricle dila-
tation (kappa 0.62–0.73) while inter-rater agreement was
moderate for atrophy of the pons and cerebellum (kappa
0.46–0.48).
The diagnostic accuracy of brain MRI to identify AP re-
sulted in an AUC of 0.82 (95 % CI 0.69–0.94) and for DTI in
an AUC of 0.75 (95 % CI 0.61–0.90), as demonstrated in
Fig. 4. The combination of brain MRI and DTI resulted in
an AUC of 0.83 (95 % CI 0.70–0.95). DTI therefore did not
significantly improve the diagnostic accuracy of brain MRI to
differentiate the group of AP from PD. Abnormalities on brain
MRI considered to be specific for MSA-P resulted in an AUC
of 0.82 (95 % CI 0.69–0.96) to identify MSA-P. The AUC
was slightly increased to 0.85 (95 % CI 0.71–0.98) when
combined with MD of the putamen.
Discussion
We evaluated the diagnostic accuracy of 3 T brain MRI and
DTI to differentiate AP from PD in early stage parkinsonism.
Unlike previous studies, we evaluated brainMRI performed at
baseline in a cohort of patients with initial uncertain clinical
diagnosis. TBSS demonstrated higher MD of the centrum
semiovale, external capsule, putamen, and superior cerebel-
lum in AP in comparison to PD. FA of the centrum semiovale
was significantly lower in AP. This pattern of differences in
diffusivity probably represents the summation of microstruc-
tural changes of different disease entities in the AP group. In
MSA-P, MD of the left putamen, left external capsule, and
superior part of the cerebellar vermis proved to be statistically
significant higher in comparison to PD, with lower FA in a
part of the left external capsule.
Results of the TBSS and the ROI methods showed some
discrepancies, such as significantly higher MD values of the
SCP and midbrain in PSP demonstrated with the ROI method
but not confirmed by TBSS. For other brain structures, results
were in accordance such as higher MD of the putamen in
MSA-P. Results of these two methods were therefore consid-
ered complementary rather than contradictory.
The diagnostic accuracy of brain MRI to identify AP as a
group was not improved when combined with the ROI mea-
surements of MD in the putamen, midbrain, and SCP, al-
though the AUC was slightly increased when evaluating the
diagnostic accuracy to identify the subgroup of MSA-P. Dis-
ease specific diagnostic measures of DTI probably give a bet-
ter estimation of the diagnostic accuracy rather grouping all
the different forms of AP together. This is illustrated by our
ROI analyses where differences in MD of the putamen or
midbrain can be identified in MSA-P or PSP, while the
Table 1 Patient characteristics
PD (n=30) AP (n=19) p value
Age (years) 61.9 (8.1) 65.5 (7.6) n.s.
Sex (M/F) 17:13 8:11 n.s.
Disease duration (months) 21.6 (11.9) 28.4 (11.1) p=0.008
UPDRS-III 31.6 (10.2) 43.5 (11.4) p<0.001
H&Y 1.7 (0.7) 2.4 (0.6) p=0.001
MMSE 28.4 (1.7) 28.1 (1.6) n.s.
Mean or number (standard deviation). Student’s t test applied to test for
group differences
n.s. not statistically significant
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averaged MD for AP as a group does not statistically differ
from PD.
We found significantly increased putaminal MD values for
MSA-P in comparison to PD. Diffusional changes of the pu-
tamen in MSA correspond to known underlying neuropatho-
logic changes in the nigrostriatal system, with more severe
involvement of the posterior part of the putamen compared
to its anterior part in MSA-P, as has been reported in previous
studies [28–33]. The chosen putaminal MD cutoff threshold
of 0.9×10−3 mm2/s is in accordance with other studies [32,
33].
Increased MD values in the midbrain and SCP in PSP as
compared to both MSA and PD, as we found, have also been
reported previously [34–38]. Histopathologic changes in PSP
include damage in the cerebellar dentate nucleus and its pro-
jection fibers in the SCP [39]. The clinical significance of
damage to the SCP in PSP was found uncertain, and degener-
ation of the SCP appears unrelated to disease duration or typ-
ical clinical findings such as gaze palsy and postural instability
[40]. It has been reported that midbrain diffusional changes in
PSP seem to correlate with disease progression [41], while in
our study, this was observed already in early disease stages.
We did not find altered diffusional measures in subcortical
gray matter structures in DLB. Possibly, white matter struc-
tures in the left frontal lobe and corpus callosum could be
affected in DLB, though the difference in MD and FA values
between PD and DLB found by our TBSS analyses were not
statistically significant. There is a debate whether DLB and
dementia in PD (PDD) are the same disease entities [42].
Subtle cognitive deficits indicating frontal lobe dysfunction
are common in early stage PD, while PDD frequently occurs
in late stages. Contradictory study results have been published
for DTI studies comparing DLB with PDD [43–46], though
these discrepancies could be attributed to differences in scan-
ning protocols and MRI field strengths. It remains to be de-
termined whether DTI could provide diagnostic markers to
identify DLB.
As many studies on DTI in parkinsonism focused on group
analyses and evaluating patients in advanced disease stages
[10], the challenge now lies in clinical application of quanti-
tative DTI in the diagnostic workup of an individual patient
presenting with parkinsonism. A major advantage of TBSS
over the ROI method is that it enables a hypothesis-free anal-
ysis of whole brain DTI. Although effects of misalignment
due to registration and smoothing are limited, TBSS is criti-
cized for problems with the required registration process and
less reliable estimation of the diffusivity at multiple fiber ori-
entation, such as crossing fibers. Drawbacks of TBSS are that
it is only suited for the evaluation of major white matter tracts
and not for gray matter structures, and diagnostic criteria for
clinical use are not readily provided which hinders the evalu-
ation of an individual patient. Quantitative measures of diffu-
sivity of an individual patient can easily be performed with the
ROI method, but for use in clinical practice validated diagnos-
tic criteria should be applied. Error correction and standard-
ized ROI placement is warranted for reliable and reproducible
quantitative DTI analysis and this should not be cumbersome.
Only few studies evaluated DTI in relation to conventional
brain MRI or other advanced MRI techniques. Focke et al.
studied DTI in relation to R2* and based on their results
R2* seems to be of value for the diagnosis of MSA and DTI
for the diagnosis of PSP [34].
Although diffusional changes are considered to represent a
quantitative measure of neurodegenerative changes in the
brain, changes are notoriously difficult to interpret due to an
insufficient understanding of the structural underpinnings of
these changes. For example, it can be debated whether diffu-
sional changes are the representation of the primary patholog-
ic process, the result of a secondary consequence or age-
related diffusional changes [47]. DiffusionMRI has been used
to get a better understanding of specific nonmotor signs of PD
such as hyposmia and depression [48–51], but those probably
represent a secondary consequence. Previous study results are
conflicting whether or not levadopa treatment would be of
influence on changes in diffusivity of different brain struc-
tures. One study reported significant differences in putaminal
ADC values between PD patients on levodopa treatment and
matched untreated patients [52], and they suggested that these
differences could be attributed to the use of levodopa. How-
ever, other studies found no effect of levodopa treatment on
FA or ADC values [53, 54].
The complexity of interpreting diffusional changes is illus-
trated by two recently published systematic reviews, which
differed in their conclusion whether DTI of the substantia
nigra can be used as a diagnostic marker for PD [8, 9].
Cochrane et al. found highly significant PD induced FA re-
duction in the substantia nigra [8]. On the contrary, Schwarz
et al. concluded that there is insufficient evidence for nigral
DTI measures to serve as a useful diagnostic marker of PD at
this point in time [9]. Differences in studies included in these
two meta-analyses as well as a variation of extracted values
from included studies could explain their contradicting
Fig. 2 TBSS analyses of atypical parkinsonism with Parkinson’s disease
and atypical parkinsonism subgroups with Parkinson’s disease. Upper
row: TBSS comparison of AP (n=19) with PD (n=29). Brain regions
with statistically significant lower FA and higher MD in AP in
comparison to PD (p<0.05). Middle row: TBSS comparison of MSA-P
(n=12) with PD (n=29). MD of the left putamen and external capsule,
and superior part of the cerebellar vermis proved to be statistically
significant higher for MSA-P in comparison to PD (p<0.05). A part of
the left external capsule demonstrated significantly lower FA in MSA-P.
Lower row: TBSS comparison of DLB (n=3) with PD (n=29). No
statistically significant differences were demonstrated, while at a p
value of <0.1 lower FA and higher MD in the left frontal lobe is seen
for DLB in comparison PD. No differences were demonstrated in a TBSS
comparison between PSP and PD. Red, lower values; blue, higher values
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conclusions. In our study, FA and MD values of the midbrain
in PD were comparable toMSA-P and DLB, and in our TBSS
analyses, no PD-specific DTI changes could be demonstrated.
It remains a debate whether or not DTI would provide a new
diagnostic measure for clinical use to identify PD in the early
disease stages.
There are some limitations to our study:
First, our study population was relatively small, especially
in relation to the number of different MRI parameters studied.
It consisted of patients presenting with predominantly hypo-
kinetic symptoms and uncertain clinical diagnosis, probably
explaining the majority of AP patients diagnosed withMSA-P
and the low prevalence of other forms of neurodegenerative
AP. It has been demonstrated that the added value of brain
MRI in the diagnostic workup of parkinsonism is highest for
those patients where the baseline certainty about the diagnosis
is lowest [6]. Based on initial clinical evaluation, patients with
probable diagnoses of PSP, DLB, CBS, and vascular parkin-
sonism were excluded from the study. The classic phenotype
of PSP, now called Richardson’s syndrome, is characterized
by early onset postural instability and falls, supranuclear gaze
palsy, and cognitive dysfunction [55]. It is the parkinsonism
form of PSP, dominated by asymmetric onset, tremor, and
moderate initial therapeutic response to levodopa, which ren-
ders the differentiation with PD difficult [56]. The same ac-
counts for corticobasal syndrome, which is suspected when
Table 2 Statistically significant
group differences in ROI
measures of MD and FA in
Parkinson’s disease and atypical
parkinsonism
ROI location PD (30) AP (19)
MSA-P (12) PSP (3) DLB (3)
Putamen right MD* 0.76 (0.14) 0.87 (0.21) 0.92 (0.22) 0.76 (0.16) 0.79 (0.18)
MSA vs PD
p=0.032
Putamen right FA 0.46 (0.09) 0.44 (0.13) 0.41 (0.15) 0.49 (0.10) 0.50 (0.05)
Putamen left MD* 0.72 (0.11) 0.82 (0.18) 0.87 (0.20) 0.77 (0.04) 0.66 (0.09)
MSA vs PD
p=0.01
Putamen left FA 0.49 (0.08) 0.46 (0.09) 0.43 (0.10) 0.50 (0.03) 0.54 (0.06)
Midbrain right MD* 0.71 (0.10) 0.75 (0.13) 0.71 (0.13) 0.92 (0.04) 0.73 (0.06)
PSP vs PD
p=0.011
PSP vs MSA
p=0.022
Midbrain right FA 0.54 (0.07) 0.56 (0.05) 0.57 (0.06) 0.52 (0.01) 0.56 (0.02)
Midbrain left MD* 0.72 (0.12) 0.86 (0.17) 0.81 (0.11) 1.15 (0.11) 0.77 (0.10)
PSP vs PD
p<0.001
PSP vs MSA
p<0.001
PSP vs DLB
p=0.002
Midbrain left FA 0.56 (0.08) 0.52 (0.8) 0.55 (0.08) 0.44 (0.01) 0.50 (0.08)
SCP right MD* 0.91 (0.15) 1.04 (0.23) 0.96 (0.23) 1.32 (0.01) 1.04 (0.11)
PSP vs PD
p=0.001
PSP vs MSA
p=0.011
SCP right FA 0.70 (0.07) 0.65 (0.10) 0.67 (0.12) 0.58 (0.02) 0.65 (0.09)
SCP left MD* 0.86 (0.10) 0.99 (0.19) 1.01 (0.21) 0.97 (0.07) 0.92 (0.18)
MSA vs PD
p=0.018
SCP left FA 0.69 (0.08) 0.66 (0.11) 0.65 (0.12) 0.66 (0.06) 0.71 (0.07)
Mean (standard deviation)MD (×10−3 mm2 /s) and FAvalues of ROI in different brain structures for PD,MSA-P,
PSP, and DLB. One-way ANOVA (corrected for multiple comparisons with a Bonferroni correction) to analyze
group differences between (*p value below 0.05 considered statistically significant). Structures with statistically
significant differences are shown in this table, see Appendix Table 4 for all structures which have been evaluated
PD Parkinson’s disease, AP neurodegenerative atypical parkinsonism, MSA-P multiple system atrophy–parkin-
sonian form, PSP progressive supranuclear palsy, DLB dementia with Lewy bodies, SCP superior cerebellar
peduncle, MD mean diffusivity, FA fractional anisotropy
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cortical dysfunction is prominent (e.g., alien limb phenome-
non, cognitive decline, or behavioral abnormalities), while the
differentiation with PD can be difficult in case of presence of
asymmetric parkinsonism and rigidity [57, 58]. Clinical pre-
sentation of vascular parkinsonism usually includes postural
instability and falls, rather than upper limb rest tremor or bra-
dykinesia [59]. As a consequence of our inclusion, our study
is underpowered to draw definite conclusions whether DTI is
of added value for the diagnosis of separate AP subgroups. On
the other side, prevalence of less frequent diseases does reflect
clinical practice and illustrates the challenges for ancillary
investigations to identify more rare causes of parkinsonism.
The new element of our study is that we evaluated whether
DTI improves the diagnostic accuracy of brain MRI to
Fig. 3 Boxplots of MD values (mm2/s) of the putamen, midbrain, and
SCP. Horizontal lines indicate the defined threshold MD values to
discriminate AP from PD (putamen and midbrain MD values of 0.9×10
and 1.1×10−3 mm2/s for the SCP). PD Parkinson’s disease, AP
neurodegenerative atypical parkinsonism, MSA-P multiple system
atrophy–parkinsonian form, PSP progressive supranuclear palsy, DLB
dementia with Lewy bodies, SCP superior cerebellar peduncle
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Table 3 Frequency of
abnormalities on conventional
brain MRI
Abnormality PD
(30), N
(%)
AP
(19), N
(%)
Inter-rater
variability
(kappa)
MSA-P
(12), N
(%)
PSP (3),
N (%)
DLB
(3), N
(%)
CBD
(1), N
(%)
Putaminal
atrophy
4 (13) 3 (16) 3 (25) 0 (0) 0 (0) 0 (0) 0.92
Putaminal T2
hypo-intensity
2 (7) 9 (47) 7 (58) 1 (33) 1 (33) 0 (0) 0.94
Putaminal rim 15 (30) 7 (37) 4 (33) 1 (33) 1 (33) 1(100) 0.00
Pons atrophy 1 (3) 2 (11) 2 (17) 0 (0) 0 (0) 0 (0) 0.48
Hot cross bun
sign
0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 1.00
Cerebellar
atrophy
4 (13) 6 (32) 3 (25) 0 (0) 3 (100) 0 (0) 0.46
MCP T2 hyper-
intensity
0 (0) 3 (16) 3 (25) 0 (0) 0 (0) 0 (0) 0.65
Midbrain
Atrophy
0 (0) 3 (16) 1 (5) 2 (67) 0 (0) 0 (0) 0.73
Hummingbird
sign
0 (0) 4 (21) 1 (5) 3 (100) 0 (0) 0 (0) 1.00
Midbrain
<14 mm
0 (0) 3 (16) 1 (5) 2 (67) 0 (0) 0 (0) 0.65
Cortical atrophy 10 (33) 9 (47) 5 (26) 1 (33) 3 (100) 0 (0) 0.62
Dilatation third
ventricle
5 (17) 12 (63) 7 (58) 3 (100) 2 (67) 0 (0) 0.67
Dilatation lateral
ventricles
4 (13) 8 (42) 4 (33) 2 (67) 2 (67) 0 (0) 0.94
Infarction 2 (7) 1 (5) 0 (0) 0 (0) 1 (33) 0 (0) 0.64
Confluent white
matter
changes
4 (13) 1 (5) 1 (5) 0 (0) 0 (0) 0 (0) 0.62
PD Parkinson’s disease, AP neurodegenerative atypical parkinsonism, MSA-P multiple system atrophy–parkin-
sonian form, PSP progressive supranuclear palsy, DLB dementia with Lewy bodies, CBD corticobasal degener-
ation, MCP middle cerebellar peduncle
Fig. 4 ROC curves of brain MRI and DTI to identify neurodegenerative
atypical parkinsonism as a group (left) and MSA-P (right). Conventional
brain MRI (1), DTI (2), and MRI with DTI combined (3). Quantitative
DTI measures of DTI did not increase the diagnostic accuracy of brain
MRI for the diagnosis of AP as a group: AUC 0.83 (95 % CI 0.70–0.95).
The AUC for theMRI diagnosis ofMSA-Pwas slightly increased byMD
of the putamen: AUC 0.82 (95%CI 0.69–0.96) was increased to 0.85 (95
% CI 0.71–0.98). AUC area under the curve, CI confidence interval,
MSA-P multiple system atrophy–parkinsonian form
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identify AP as a group in case of uncertainty about the clinical
diagnosis, where it is of the most clinical relevance. Our pa-
tient cohort did not include patients diagnosed with MSA-C
(clinical presentation distinct from PD and MSA-P with pre-
dominant cerebellar symptoms), which could explain that no
significant diffusion differences of the MCP and pons were
found in MSA-P, although diffusional changes in these struc-
tures have also been reported in MSA-P [32, 33, 60]. Al-
though vascular parkinsonism was beyond the scope of our
study, DTI could be of value for the diagnosis of vascular
parkinsonism [61, 62]. Further studies are warranted and
should include a larger sample size to evaluate the additional
value of DTI for improved differentiation between the various
atypical parkinsonism subtypes in the early disease stages.
Second, we did not have post mortem confirmation to
reach the gold standard diagnosis and cannot fully exclude
misdiagnosis. Clinical follow-up enabled us to improve cer-
tainty of the diagnosis. It has been shown that in the hands of
an experienced movement disorder specialist, clinical follow-
up for at least 2 years enables accurate diagnosis by evaluating
the rate of disease progression, treatment response and devel-
opment of any red flags [5].
Third, interpretation of the reported quantitative MD and
FA values should be done with caution because comparisons
of diffusional values in different studies is difficult as scanning
protocols and post processing of diffusional data lack stan-
dardization. It is known that MD and FA values vary with
the MRI field strength used [63]. As DTI is sensitive to sus-
ceptibility changes, FA and MD values are probably influ-
enced by brain iron accumulation and calcification [9]. Future
studies need to elucidate to what extent quantitative diffusion
analysis should be corrected for tissue susceptibility changes,
taking the MRI field strength into account. Furthermore, frac-
tional anisotropy is derived from the first, second, and third
eigenvectors (and subsequent eigenvalues), which could pro-
vide additional measures of microstructural integrity of brain
tissue. Parallel imaging and other accelerating techniques en-
able acquisition of high resolution DTI [64], which could be
superior for the detection of more subtle neurodegenerative
changes at acceptable scanning times to enable clinical appli-
cation but this needs to be determined in future prospective
clinical cohort studies. In a case-control study evaluating sub-
jects with PD, it has been reported that diffusional kurtosis
imaging, which enables the quantification of non-Gaussian
diffusion, is a more sensitive technique than conventional
DTI for assessing tissue microstructure, even in the presence
of crossing fibers [65].
Finally, although the diagnostic accuracy of brain MRI in
our study was not improved by DTI using the current analyses
approach, we cannot exclude that it will prove to be of added
value for the diagnostic work-up of parkinsonism while using
a different methods of analysis. A previous study using a
slightly different ROI approach with multiple DTI measures
in the basal ganglia and cerebellum reported high accuracy in
classifying patients with PD, MSA-P, PSP and control sub-
jects [11]. The ROI method is restricted because only a few
ROIs are chosen based on a priori hypothesis and diffusional
changes outside the ROI are not analyzed. Furthermore, it
bears the pitfall of partial volume averaging of MD and FA
measurements. Although whole brain analyses were per-
formed with TBSS, this method is less suitable for evaluating
gray matter structures as has been discussed earlier.
Machine-learning algorithms have been developed for ad-
vancedMR imaging techniques, and initial results of applying
this technique to analyze DTI in a cohort of patients with
parkinsonism are promising [66]. These machine-learning
techniques rely on algorithms analyzing imaging data without
a priori hypotheses, based on which classifiers can be con-
structed for pattern recognition at the individual level [67,
68]. Comparedwith a single imaging technique, the advantage
of using multiple techniques is to extract more features in
order to more accurately profile specific neurodegenerative
pathology [68].
Conclusion
In early stage parkinsonism, distinct brain regions showed
higher mean diffusivity and lower fractional anisotropy values
in the atypical parkinsonism group as compared to
Parkinson’s disease. Using a ROI approach, increased MD
measures of the putamen, midbrain, and superior cerebellar
peduncles seem appropriate for differentiating AP from PD.
The diagnostic accuracy of brain MRI in the identification of
atypical parkinsonism as a group was not improved by the
current analysis approach to DTI, though it could be of added
value to identify atypical parkinsonism subgroups.
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Appendix
Table 4 ROI measures of MD and FA in Parkinson’s disease and atypical parkinsonism
ROI location PD (30) AP (19)
MSA-P (12) PSP (3) DLB (3)
Caudate nucleus right MD 0.77 (0.16) 0.73 (0.18) 0.66 (0.17) 0.94 (0.06) 0.82 (0.11)
Caudate nucleus right FA 0.43 (0.07) 0.47 (0.09) 0.50 (0.11) 0.42 (0.03) 0.44 (0.03)
Caudate nucleus left MD 0.93 (0.21) 0.95 (0.25) 0.86 (0.22) 1.24 (0.18) 1.10 (0.25)
Caudate nucleus left FA 0.37 (0.07) 0.39 (0.07) 0.43 (0.06) 0.30 (0.05) 0.37 (0.09)
Putamen right MD* 0.76 (0.14) 0.87 (0.21) 0.92 (0.22) 0.76 (0.16) 0.79 (0.18)
MSA vs PD p=0.032
Putamen right FA 0.46 (0.09) 0.44 (0.13) 0.41 (0.15) 0.49 (0.10) 0.50 (0.05)
Putamen left MD* 0.72 (0.11) 0.82 (0.18) 0.87 (0.20) 0.77 (0.04) 0.66 (0.09)
MSA vs PD p=0.01
Putamen left FA 0.49 (0.08) 0.46 (0.09) 0.43 (0.10) 0.50 (0.03) 0.54 (0.06)
GP right MD 0.77 (0.23) 0.79 (0.23) 0.75 (0.22) 0.84 (0.07) 0.93 (0.36)
GP right FA 0.54 (0.11) 0.54 (0.11) 0.56 (0.09) 0.56 (0.02) 0.53 (0.16)
GP left MD 0.76 (0.23) 0.55 (0.09) 0.83 (0.25) 0.65 (0.05) 0.86 (0.32)
GP left FA 0.56 (0.11) 0.54 (0.11) 0.53 (0.11) 0.61 (0.05) 0.52 (0.14)
Thalamus right MD 0.71 (0.06) 0.76 (0.12) 0.76 (0.14) 0.73 (0.08) 0.77 (0.11)
Thalamus right FA 0.53 (0.06) 0.53 (0.08) 0.53 (0.10) 0.57 (0.05) 0.51 (0.06)
Thalamus left MD 0.70 (0.08) 0.71 (0.09) 0.71 (0.10) 0.72 (0.10) 0.70 (0.05)
Thalamus left FA 0.50 (0.06) 0.50 (0.08) 0.49 (0.09) 0.54 (0.03) 0.53 (0.05)
Midbrain right MD* 0.71 (0.10) 0.75 (0.13) 0.71 (0.13) 0.92 (0.04) 0.73 (0.06)
PSP vs PD p=0.011
PSP vs MSA p=0.022
Midbrain right FA 0.54 (0.07) 0.56 (0.05) 0.57 (0.06) 0.52 (0.01) 0.56 (0.02)
Midbrain left MD* 0.72 (0.12) 0.86 (0.17) 0.81 (0.11) 1.15 (0.11) 0.77 (0.10)
PSP vs PD p<0.001
PSP vs MSA p<0.001
PSP vs DLB p=0.002
Midbrain left FA 0.56 (0.08) 0.52 (0.8) 0.55 (0.08) 0.44 (0.01) 0.50 (0.08)
Pons MD 0.75 (0.12) 0.72 (0.13) 0.69 (0.15) 0.73 (0.05) 0.79 (0.12)
Pons FA 0.52 (0.07) 0.54 (0.08) 0.55 (0.09) 0.55 (0.06) 0.51 (0.11)
SCP right MD* 0.91 (0.15) 1.04 (0.23) 0.96 (0.23) 1.32 (0.01) 1.04 (0.11)
PSP vs PD p=0.001
PSP vs MSA p=0.011
SCP right FA 0.70 (0.07) 0.65 (0.10) 0.67 (0.12) 0.58 (0.02) 0.65 (0.09)
SCP left MD* 0.86 (0.10) 0.99 (0.19) 1.01 (0.21) 0.97 (0.07) 0.92 (0.18)
MSA vs PD p=0.018
SCP left FA 0.69 (0.08) 0.66 (0.11) 0.65 (0.12) 0.66 (0.06) 0.71 (0.07)
MCP right MD 0.64 (0.07) 0.66 (0.08) 0.64 (0.10) 0.67 (0.03) 0.68 (0.06)
MCP right FA 0.72 (0.06) 0.68 (0.08) 0.70 (0.09) 0.69 (0.04) 0.63 (0.06)
MCP left MD 0.65 (0.05) 0.66 (0.09) 0.68 (0.09) 0.66 (0.08) 0.61 (0.11)
MCP left FA 0.71 (0.06) 0.70 (0.07) 0.69 (0.07) 0.76 (0.05) 0.70 (0.09)
Dentate nucleus right MD 0.73 (0.10) 0.76 (0.13) 0.72 (0.10) 0.83 (0.10) 0.88 (0.21)
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